688271:SSEShanghai United Imaging Healthcare Co., Ltd. Class A Analysis
Data as of 2026-05-29 - not real-time
CN¥120.30
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Shanghai United Imaging Healthcare is trading at CNY 120.3, comfortably above its 20‑day (115.1) and 50‑day (114.5) simple moving averages, with a bullish MACD histogram (+0.97) and a neutral RSI (56.8). Volume is on an upward trend, support sits near 109.1 and resistance around 130.8, while its 30‑day volatility spikes at 42% yet beta remains low at 0.17, indicating limited market‑wide risk.
Fundamentally, the company posted 17% revenue growth and strong gross margins, but its valuation is stretched: a trailing P/E of 52 versus an industry average of 28 and a DCF‑derived fair value of roughly 56 suggest overvaluation. Dividend yield is modest at 0.17% with a low payout ratio, and free cash flow is negative despite positive operating cash flow. Recent ESG rating upgrades and accelerated global expansion, highlighted in the latest annual report, provide a growth narrative that may justify a premium, though debt‑to‑equity is elevated.
Fundamentally, the company posted 17% revenue growth and strong gross margins, but its valuation is stretched: a trailing P/E of 52 versus an industry average of 28 and a DCF‑derived fair value of roughly 56 suggest overvaluation. Dividend yield is modest at 0.17% with a low payout ratio, and free cash flow is negative despite positive operating cash flow. Recent ESG rating upgrades and accelerated global expansion, highlighted in the latest annual report, provide a growth narrative that may justify a premium, though debt‑to‑equity is elevated.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price above short‑term SMAs with bullish MACD
- Elevated valuation (P/E 52) vs industry
- Increasing trading volume supporting near‑term stability
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustained revenue growth and expanding global footprint
- Continued overvaluation relative to DCF fair value
- Low beta and strong liquidity mitigating market swings
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong growth outlook backed by ESG upgrade and international expansion
- High gross and operating margins indicating competitive advantage
- Dividend sustainability and low payout ratio supporting shareholder returns
Key Metrics & Analysis
Financial Health
Revenue Growth17.30%
Profit Margin13.34%
P/E Ratio52.1
ROE8.86%
ROA3.88%
Debt/Equity7.42
P/B Ratio4.5
Op. Cash FlowCN¥2.1B
Free Cash FlowCN¥-1365633408
Industry P/E27.8
Technical Analysis
TrendNeutral
RSI56.8
SupportCN¥109.14
ResistanceCN¥130.76
MA 20CN¥115.11
MA 50CN¥114.54
MA 200CN¥130.28
MACDBullish
VolumeIncreasing
Fear & Greed Index93.14
Valuation
Fair ValueCN¥56.24
GradeOvervalued
TypeGrowth
Dividend Yield0.17%
Risk Assessment
Beta0.17
Volatility42.28%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.